Healthcare Services

Gastrointestinal Cancer Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Gastrointestinal Cancer Market Evolve From 2026 To 2030?

The gastrointestinal cancer market has witnessed significant expansion in recent years. Its valuation is anticipated to grow from $27.05 billion in 2025 to $30.33 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.1%. The increase observed in the past can be ascribed to a rising prevalence of gastrointestinal cancers, the enhancement of diagnostic imaging capabilities, increased public awareness regarding early cancer detection, advancements in oncology drug development, and improved access to facilities for cancer treatment.

The gastrointestinal cancer market is projected to experience significant expansion in the coming years. Its valuation is set to reach $47.4 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.8%. This expansion during the forecast period is driven by factors such as greater investments in personalized oncology, the increasing embrace of biomarker-based diagnostics, the broadening of immuno-oncology treatment pipelines, an uptick in the utilization of minimally invasive diagnostics, and enhanced healthcare spending on cancer treatment. Key trends observed over this period encompass a wider acceptance of targeted GI cancer therapies, the growing application of molecular diagnostics, a heightened emphasis on combination immunotherapy approaches, the extension of early cancer screening initiatives, and improved integration of precision medicine.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24546&type=smp

What Drivers Are Influencing The Gastrointestinal Cancer Market?

The increasing embrace of targeted therapies is projected to fuel the expansion of the gastrointestinal cancer market in the coming years. These therapies represent treatments specifically designed to inhibit the proliferation of cancer cells by targeting particular molecular structures, thereby minimizing damage to healthy cells. Their mechanism involves acting on distinct molecular pathways or genetic alterations responsible for driving a disease, particularly in oncology. In contrast to conventional treatments such as chemotherapy, which indiscriminately affect both healthy and cancerous cells, targeted therapies concentrate on the specific attributes of a patient’s condition. For gastrointestinal (GI) cancer, targeted therapies operate on particular genes or proteins that regulate tumor development, leading to highly accurate and effective treatment. This approach yields improved results with fewer adverse reactions compared to standard chemotherapy. As an illustration, in July 2023, data from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, showed that at the close of quarter one (Q1) 2023, there were 247 gene therapies in Phase II, a figure that increased by 5% to reach 260 by the conclusion of quarter two (Q2). Consequently, the growing utilization of targeted therapies is propelling the growth of the gastrointestinal cancer market.

Which Segment Areas Are Covered In The Gastrointestinal Cancer Market Analysis?

The gastrointestinal cancer market covered in this report is segmented –

1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

How Are Trends Shaping The Direction Of The Gastrointestinal Cancer Market?

Companies operating within the gastrointestinal cancer market are prioritizing the creation of advanced solutions, including monoclonal antibody treatment, to both enhance patient survival rates and mitigate treatment-related side effects. Monoclonal antibody treatment functions by utilizing laboratory-engineered antibodies that accurately identify and attach to cancer cells, thereby assisting the immune system in pinpointing and eradicating them. For instance, in September 2024, Japan-based pharmaceutical company Astellas Pharma Inc. released VYLOY (zolbetuximab) in conjunction with fluoropyrimidine- and platinum-containing chemotherapy, following its approval from the European Commission. This medication is designated as a first-line therapy for adults suffering from locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, provided their tumors express claudin 18.2 (CLDN18.2). This significant approval positions VYLOY as the initial and sole therapeutic option in the European Union specifically targeting CLDN18.2, a biomarker present in approximately 38% of such patients, based on compelling clinical trial outcomes from the SPOTLIGHT and GLOW studies.

Which Global Companies Are Actively Competing In The Gastrointestinal Cancer Market?

Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd

Read the full gastrointestinal cancer market report here:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Gastrointestinal Cancer Market?

North America was the largest region in the gastrointestinal cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gastrointestinal Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24546&type=smp

Browse Through More Reports Similar to the Global Gastrointestinal Cancer Market 2026, By The Business Research Company

Gastroesophageal Reflux Disease Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report

Gastroparesis Global Market Report

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Barretts Esophagus Global Market Report

https://www.thebusinessresearchcompany.com/report/barretts-esophagus-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795